Literature DB >> 15944924

Clinicopathologic and prognostic significance of cyclooxygenase-2 expression in endometrial carcinoma.

M Lambropoulou1, G Alexiadis, V Limberis, N Nikolettos, G Tripsianis.   

Abstract

BACKGROUND: Endometrial carcinoma is the most common malignancy of the female genital tract in the Western world. COX-2 is highly expressed in endometrial carcinoma, but there is controversy regarding its clinical role and its possible prognostic role. COX-2 expression was determined by immuno-histochemistry and was correlated to standard clinico-pathologic variables in a series of primary untreated endometrial carcinoma patients. COX-2 as an accurate predictor of the disease was also analyzed.
METHODS: One-hundred and ten cases of primary untreated endometrial carcinoma hosts who were admitted to the Department of Obstetrics and Gynecology, University General Hospital of Alexandroupolis, were investigated. Immunohistochemistry was performed using rabbit polyclonal antiserum against human COX-2.
RESULTS: Twenty-eight patients (25.5%) were scored as COX-2 positive. A statistically significant association was found between COX-2 overexpression and FIGO stage (p=0.010). A positive correlation was also found with histological grade (p=0.019) and myometrial invasion (p=0.026). No significant association was found with histologic type of the tumor (p=0.164). COX-2 positive patients had a significant association with sort survival (p=0.028).
CONCLUSIONS: COX-2 expression is an independent clinicopathologic factor and an independent prognostic factor in endometrial carcinoma. It could be used to plan treatment modalities for hosts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15944924     DOI: 10.14670/HH-20.753

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  5 in total

Review 1.  Immunotherapy in endometrial cancer: rationale, practice and perspectives.

Authors:  Wenyu Cao; Xinyue Ma; Jean Victoria Fischer; Chenggong Sun; Beihua Kong; Qing Zhang
Journal:  Biomark Res       Date:  2021-06-16

2.  Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients.

Authors:  Maria Lambropoulou; Nikolaos Papadopoulos; Grigoris Tripsianis; George Alexiadis; Olga Pagonopoulou; Anastasia Kiziridou; Vassilios Liberis; Stylianos Kakolyris; Ekaterini Chatzaki
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-16       Impact factor: 4.553

3.  Co-expression of galectin-3 and CRIP-1 in endometrial cancer: prognostic value and patient survival.

Authors:  Maria Lambropoulou; Theodora-Eleftheria Deftereou; Sryridon Kynigopoulos; Anargyros Patsias; Constantinos Anagnostopoulos; Georgios Alexiadis; Athanasia Kotini; Alexandra Tsaroucha; Christina Nikolaidou; Anastasia Kiziridou; Nikolaos Papadopoulos; Ekaterini Chatzaki
Journal:  Med Oncol       Date:  2015-12-26       Impact factor: 3.064

4.  Cyclooxygenase-2 and β-Catenin as Potential Diagnostic and Prognostic Markers in Endometrial Cancer.

Authors:  Lin Deng; Haiyan Liang; Yi Han
Journal:  Front Oncol       Date:  2020-02-21       Impact factor: 6.244

5.  Prospects of NSAIDs administration as double-edged agents against endometrial cancer and pathological species of the uterine microbiome.

Authors:  Olga Kuźmycz; Paweł Stączek
Journal:  Cancer Biol Ther       Date:  2020-03-15       Impact factor: 4.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.